• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

    5/14/25 4:12:16 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $XFOR alert in real time by email

    Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor

    Majority of physicians and chronic neutropenia participants chose to significantly reduce G-CSF dosing when using mavorixafor in combination therapy

    BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the acceptance of two abstracts for poster presentation at the 30th Annual Congress of the European Hematology Association (EHA) taking place in Milan, Italy from June 12-15, 2025. The abstracts published online today summarize the clinical results from the company's completed Phase 2 trial of mavorixafor in the treatment of certain primary chronic neutropenic (CN) disorders.

    "We are excited to present the positive data from our completed Phase 2 trial of chronic treatment of CN participants with mavorixafor to the global hematology community for the first time," said Christophe Arbet-Engels, MD, PhD, Chief Medical Officer of X4 Pharmaceuticals. "With enrollment progressing in our ongoing pivotal Phase 3 trial in CN, we continue to look at these Phase 2 results as supportive of the design of the Phase 3 trial and a signal of its potential for success. Mavorixafor is the first innovation to be studied for the treatment of CN in more than 30 years and would be the first oral treatment available for this serious condition if approved."

    Summary of EHA Posters to be Presented:

    The Phase 2 study of oral, once-daily mavorixafor was a six-month, open-label clinical trial that enrolled a total of 23 participants diagnosed with idiopathic, congenital, or cyclic chronic neutropenia. The two poster presentations at EHA will focus on clinical results based on the following goals of the study:

    • Assessing safety and the ability of oral, once-daily mavorixafor to sustainably raise absolute neutrophil count (ANC) as a monotherapy and in combination with injectable granulocyte colony-stimulating factor (G-CSF); and
    • Assessing whether treatment of participants with mavorixafor could enable the reduction of G-CSF dosage while maintaining clinically targeted ANC levels and physicians' willingness to do so.

    Evaluating the Safety and Efficacy of Mavorixafor, an Oral CXCR4 Antagonist, in Patients with Chronic Neutropenic Disorders: Results from the Phase 2 Study

    Lead Author: Julia T. Warren, MD, PhD, Department of Pediatrics, Division of Hematology, Perelman School of Medicine, University of Pennsylvania, and Division of Pediatric Hematology, Children's Hospital of Philadelphia

    Poster #: PS1654

    Poster Session: Bone marrow failure syndromes incl. PNH - Clinical

    Date Available: Thursday, June 12

    Mavorixafor, an Oral CXCR4 antagonist, Allows for Granulocyte-Colony Stimulating Factor Dose De-escalation in Patients with Chronic Idiopathic Neutropenia and Congenital Neutropenia

    Lead Author: Julia T. Warren, MD, PhD, Department of Pediatrics, Division of Hematology, Perelman School of Medicine, University of Pennsylvania, and Division of Pediatric Hematology, Children's Hospital of Philadelphia

    Poster #: PS1669

    Poster Session: Bone marrow failure syndromes incl. PNH - Clinical

    Date Available: Thursday, June 12

    About Chronic Neutropenia and Mavorixafor

    Chronic neutropenia is a primary, rare blood condition lasting more than three months, persistently or intermittently, and characterized by low levels of circulating neutrophils, increased risk of infections, and reduced quality of life. Neutrophils are retained in the bone marrow by the CXCR4/CXCL12 axis, creating a reserve of cells. Downregulation of the CXCR4 receptor by mavorixafor, an orally active CXCR4 antagonist, has been shown to mobilize functional neutrophils from the bone marrow into the peripheral blood across multiple disease states. The level of circulating neutrophils is typically measured by drawing blood to determine the absolute neutrophil count (ANC).

    About the Phase 1b/Phase 2 Chronic Neutropenia Trial

    The Phase 1b/Phase 2 clinical trial (NCT04154488) was a proof-of-concept, open-label, multicenter study designed to assess oral mavorixafor, with or without injectable G-CSF, in participants with chronic neutropenic disorders, including idiopathic, cyclic, and congenital neutropenia. In the Phase 1b portion of the study (n=25), participants received one dose of oral mavorixafor and were assessed for magnitude of absolute neutrophil count (ANC) response and tolerability. The Phase 2 portion of the trial (n=23) assessed the safety, tolerability, and the impact on participants' neutropenia of oral, once-daily mavorixafor with and without concurrent injectable G-CSF therapy over a six-month period in the same patient population.

    About the 4WARD Global, Pivotal Phase 3 Clinical Trial

    The 4WARD trial is a global, pivotal Phase 3 clinical trial (NCT06056297) evaluating the efficacy, safety, and tolerability of oral, once-daily mavorixafor (with or without G-CSF) in people with congenital, acquired primary autoimmune, or idiopathic chronic neutropenia who are experiencing recurrent and/or serious infections. The 52-week trial is a randomized, double-blind, placebo-controlled, multicenter study aiming to enroll 150 participants with confirmed trough ANC levels less than 1,000 cells per microliter at baseline screening and histories of two or more serious and/or recurrent infections in the prior year. The primary endpoint of the trial is based on two outcome measures: annualized infection rate and positive ANC response.

    About X4 Pharmaceuticals

    X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging expertise in CXCR4 and immune system biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.

    X4 Forward Looking Statements

    This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target," or other similar terms or expressions that concern X4's expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, implied or express statements regarding the initiation, timing, progress, and results of our current and future preclinical studies and clinical trials.

    Any forward-looking statements in this press release are based on management's current expectations and beliefs. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond X4's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: trials, studies and research programs may be delayed and may not have satisfactory outcomes, additionally earlier trials and studies may not be predictive of later trials and studies, including assessing the ability of mavorixafor monotherapy to durably increase absolute neutrophil count in patients with chronic neutropenic; the design and rate of enrollment for current clinical trials may not enable successful completion of the trial(s); X4 may be unable to obtain and maintain regulatory approvals; adverse safety effects may arise from the testing or use of X4's product and product candidates; and other risks and uncertainties, including those described in the section entitled "Risk Factors" in X4's most recent Annual Report on X4's Form 10-K, as well as in other filings X4 makes with the Securities and Exchange Commission, including its quarterly report on Form 10-Q, from time to time. X4 undertakes no obligation to update the information contained in this press release to reflect new events or circumstances, except as required by law.

    X4 Investor Contact: X4 Media Contact:
    Daniel Ferry Rhiannon Jeselonis
    LifeSci Advisors Ten Bridge Communications
    [email protected] [email protected]
    (617) 430-7576  
       


    Primary Logo

    Get the next $XFOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XFOR

    DatePrice TargetRatingAnalyst
    12/12/2023$3.00 → $1.00Buy → Neutral
    B. Riley Securities
    8/30/2023$3.00Buy
    B. Riley Securities
    12/22/2022$3.00Overweight
    Cantor Fitzgerald
    12/12/2022$3.00Overweight
    Piper Sandler
    12/14/2021$21.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $XFOR
    Financials

    Live finance-specific insights

    See more
    • X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful outcome of 4WARD trial XOLREMDI® net U.S. revenues $3.5 million since May 2024 launch Conference call and webcast today at 8:30 am ET BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2025, and highlighted key recent events and expected upcoming milestones. "The first quarter of 2025 was an

      5/1/25 6:01:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

      BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will report financial results for the first quarter ended March 31, 2025 and provide corporate updates on Thursday, May 1, 2025. The company will host a conference call and webcast on the same day at 8:30 a.m. EDT. The conference call can be accessed by dialing 1-800-343-4849 from the United States or 1-203-518-9848 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals' website at www.x4pharma.com. Foll

      4/24/25 8:03:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026 4WARD trial protocol refined, increasing confidence in successful outcome 2024 XOLREMDI® net revenues $2.6 million since May launch; company expects ramp up in 2025 as targeted physician outreach increases patient finding and pull-through Conference call and webcast today at 8:30 am ET BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the fourth quarter and full year

      3/25/25 6:01:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $XFOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Thoren Natasha Fay claimed ownership of 6,984 shares (SEC Form 3)

      3 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      6/3/25 6:12:48 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: Chief Commercial Officer Baldry Mark was granted 1,032 shares, increasing direct ownership by 4% to 25,337 units (SEC Form 4)

      4/A - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      6/3/25 5:01:06 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Commercial Officer Baldry Mark bought $2,561 worth of shares (1,032 units at $2.48), increasing direct ownership by 4% to 25,337 units (SEC Form 4)

      4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      5/20/25 4:51:03 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $XFOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on May 30, 2025, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the "2019 Inducement Plan"). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 5,545 shares of X4's common stock. These stock awards were granted as an inducement material to the new employees entering i

      6/2/25 4:05:00 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

      Meaningful and durable increases in functional neutrophils observed over 6-month trial with oral once-daily mavorixafor Majority of physicians and chronic neutropenia participants chose to significantly reduce G-CSF dosing when using mavorixafor in combination therapy BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the acceptance of two abstracts for poster presentation at the 30th Annual Congress of the European Hematology Association (EHA) taking place in Milan, Italy from June 12-15, 2025. The abstracts published online today summarize the clinica

      5/14/25 4:12:16 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

      4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026 Additional analyses of mavorixafor clinical trial data increase confidence in successful outcome of 4WARD trial XOLREMDI® net U.S. revenues $3.5 million since May 2024 launch Conference call and webcast today at 8:30 am ET BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2025, and highlighted key recent events and expected upcoming milestones. "The first quarter of 2025 was an

      5/1/25 6:01:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $XFOR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for XOLREMDI issued to X4 PHARMACEUTICALS INC

      Submission status for X4 PHARMACEUTICALS INC's drug XOLREMDI (ORIG-1) with active ingredient MAVORIXAFOR has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218709, Application Classification: Type 1 - New Molecular Entity

      4/29/24 2:36:51 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $XFOR
    SEC Filings

    See more
    • SEC Form 10-Q filed by X4 Pharmaceuticals Inc.

      10-Q - X4 Pharmaceuticals, Inc (0001501697) (Filer)

      5/1/25 9:22:18 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - X4 Pharmaceuticals, Inc (0001501697) (Filer)

      5/1/25 6:25:29 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by X4 Pharmaceuticals Inc.

      DEF 14A - X4 Pharmaceuticals, Inc (0001501697) (Filer)

      4/25/25 4:44:31 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $XFOR
    Leadership Updates

    Live Leadership Updates

    See more
    • X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors

      BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (NASDAQ:XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the appointment of R. Keith Woods as an independent director to the company's Board of Directors. "We are thrilled to welcome Keith to the X4 Board of Directors," said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals. "With his broad and deep experience in commercialization, international operations, supply chain, and business strategy, as well as his recent successful global launch of a rare disease product, we believe it is a great time for him to be joining X4 as a director a

      10/18/23 8:00:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer

      A seasoned leader in the launch of rare and specialty pharmaceuticals, Mr. Baldry is expected to join X4 on November 3, 2022 BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, today announced the appointment of Mark Baldry to the position of Chief Commercial Officer. In this key role, Mr. Baldry will lead all pre-commercial and product launch efforts for the company's lead therapeutic candidate, mavorixafor, a small molecule being developed as a once-daily oral therapy for chronic neutropenic disorders, including WHIM syndrome.

      10/26/22 8:00:00 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

      WALTHAM, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the appointment of Carrie Melvin as Chief Operating Officer, a newly created position at the company. "As we prepare for late-stage clinical development for our TED programs, we are excited to add Carrie to the Viridian team" said Jonathan Violin, Ph.D., Viridian Therapeutics' President and CEO. "Carrie's extensive experience in a wide range of operational activities supporting product development and approval will be tremendously valuable to our expanding

      6/23/22 7:00:00 AM ET
      $GSK
      $KURA
      $VRDN
      $XFOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
      Biotechnology: Biological Products (No Diagnostic Substances)

    $XFOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • X4 Pharmaceuticals downgraded by B. Riley Securities with a new price target

      B. Riley Securities downgraded X4 Pharmaceuticals from Buy to Neutral and set a new price target of $1.00 from $3.00 previously

      12/12/23 8:15:43 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • B. Riley Securities resumed coverage on X4 Pharmaceuticals with a new price target

      B. Riley Securities resumed coverage of X4 Pharmaceuticals with a rating of Buy and set a new price target of $3.00

      8/30/23 7:46:17 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald initiated coverage on X4 Pharmaceuticals with a new price target

      Cantor Fitzgerald initiated coverage of X4 Pharmaceuticals with a rating of Overweight and set a new price target of $3.00

      12/22/22 7:56:33 AM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $XFOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by X4 Pharmaceuticals Inc.

      SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

      11/12/24 5:59:35 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by X4 Pharmaceuticals Inc.

      SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

      11/4/24 2:15:54 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by X4 Pharmaceuticals Inc. (Amendment)

      SC 13G/A - X4 Pharmaceuticals, Inc (0001501697) (Subject)

      2/14/24 7:36:59 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $XFOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Baldry Mark bought $2,561 worth of shares (1,032 units at $2.48), increasing direct ownership by 4% to 25,337 units (SEC Form 4)

      4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      5/20/25 4:51:03 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Commercial Officer Baldry Mark bought $19,252 worth of shares (35,050 units at $0.55) and was granted 600,000 shares, increasing direct ownership by 675% to 729,173 units (SEC Form 4)

      4 - X4 Pharmaceuticals, Inc (0001501697) (Issuer)

      2/14/25 4:08:25 PM ET
      $XFOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care